Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$46.05 USD

46.05
653,296

+0.12 (0.26%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $46.04 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Debanjana Dey headshot

4 MedTech Stocks to Scoop Up Amid the Coronavirus Crisis

Here are some MedTech stocks that are expected to provide some respite to investors amid the turmoil.

Urmimala Biswas headshot

3 Medical Stocks Poised to Trounce Market on Coronavirus Scare

Here are three Medical stocks showing early signs of stellar growth, banking on the choppy global market scenario.

Is QIAGEN N.V. (QGEN) Outperforming Other Medical Stocks This Year?

Is (QGEN) Outperforming Other Medical Stocks This Year?

BD (BDX) & BioGX Submit EUA to Speed Up Coronavirus Screening

BD (BDX) expects screening to ramp up by 1,000 per day once authorized.

QIAGEN's Coronavirus Test Kit Development Gets BARDA Funding

QIAGEN (QGEN) receives support from the government to accelerate the development of the QIAstat-Dx test kit to detect the coronavirus causing virus.

BD MAX Gets CE Mark for Coronavirus Detection, Shares Up

BD (BDX) and Spain's CerTest Biotec collaborate to detect the COVID-19 in Europe.

LabCorp (LH) Launches Test to Detect Presence of Coronavirus

LabCorp (LH), with an aim to contain the outbreak of coronavirus, launches the LabCorp 2019 Novel Coronavirus (COVID-19), NAA test.

Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities

Zacks.com featured highlights include: LGI Homes, Coherus Biosciences, QIAGEN, Regeneron Pharmaceuticals and Century Communities

Sriparna Ghosal headshot

3 MedTech Stocks to Rebound After Coronavirus-Led Recoil

As the coronavirus chaos continues to rise, MedTech firms have been witnessing a spike in demand for protective respiratory equipment.

5 Stocks Trading Near 52-Week High That Can Scale Higher

Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.

Why Is Qiagen (QGEN) Up 19% Since Last Earnings Report?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Company News for Mar 4, 2020

Companies in the news are: SCON, OMER, QGEN, TLRY

Thermo Fisher (TMO) to Buy Molecular Diagnostics Major QIAGEN

Thermo Fisher (TMO) expects QIAGEN's strong molecular diagnostics presence to complement its specialty diagnostics capabilities.

Will QIAGEN Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in QIAGEN.

Dropbox, Groupon, QIAGEN, Zoom Video Communications and Novavax highlighted as Zacks Bull and Bear of the Day

Dropbox, Groupon, QIAGEN, Zoom Video Communications and Novavax highlighted as Zacks Bull and Bear of the Day

Sreyoshi Mukherjee headshot

3 Stocks Are Gaining Even as Coronavirus Creates Chaos

While key players in the United States are struggling to cope, the coronavirus has been a boon for some.

The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher

The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher

QIAGEN Ships Test Kits to China for Detecting Coronavirus

QIAGEN (QGEN) expands the molecular testing portfolio by shipping QIAstat-Dx Respiratory 2019-nCoV Panel to China for faster detection of coronavirus SARS-CoV-2.

Sriparna Ghosal headshot

Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On

The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.

QIAGEN Launches CE-Marked Breast Cancer Test Kit in Europe

QIAGEN (QGEN) launches latest diagnostics test kit in Europe to combat advanced breast cancer, following the CE Mark receipt.

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Expand

QIAGEN (QGEN) registered revenue growth across majority of its geographies and each of its operating segments in Q4

Qiagen (QGEN) Q4 Earnings and Revenues Beat Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 9.09% and 1.12%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth

Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALXN vs. QGEN: Which Stock Should Value Investors Buy Now?

ALXN vs. QGEN: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now

Investors can retain QIAGEN (QGEN) stock for now, thanks to its solid prospects.